Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10180595 | 0.89 | KAT6A (0.48) | CA2METAP2CNR2GRM2GRM3 | |
| SCHEMBL27859841 | 0.87 | HTR6 (0.57) | LPLLIPGCA2SMN1; SMN2METAP2 | |
| SCHEMBL10181083 | 0.86 | PSIP1 (0.48) | LPLLIPGCA2SMN1; SMN2METAP2 | |
| SCHEMBL20178524 | 0.84 | CA2 (0.64) | LPLLIPGCA2SMN1; SMN2HTR6 | |
| SCHEMBL9445888 | 0.84 | LPL (0.50) | LPLLIPGCA2SMN1; SMN2METAP2 | |
| SCHEMBL5662465 | 0.84 | TBXA2R (0.49) | CA2SMN1; SMN2GRM2GRM3HTR6 | |
| SCHEMBL5429891 | 0.83 | CYP4F2 (0.51) | LPLLIPGCA2GRM2GRM3 | |
| SCHEMBL28463511 | 0.83 | CA2 (0.49) | LPLLIPGCA2SMN1; SMN2METAP2 | |
| SCHEMBL28032889 | 0.83 | LPL (0.49) | LPLLIPGCA2SMN1; SMN2METAP2 | |
| SCHEMBL10180036 | 0.83 | HTR6 (0.66) | LPLLIPGCA2SMN1; SMN2METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200407339-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE | 2020-12-31 | — | — | US | disclosed |
| US-20130244122-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME | ONUKI MASAMICHI (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20120219866-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-08-30 | — | — | US | disclosed |
| EP-2475041-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE BATTERY COMPRISING SAME | Mitsubishi Chemical Corporation (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407339-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF | PTGER1, LOXL1, COL1A1 | LPL 913/4885LIPG 127/4885CA2 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.